{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:57:23Z","timestamp":1783443443426,"version":"3.54.6"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T00:00:00Z","timestamp":1521849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00520-018-4155-8","type":"journal-article","created":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T23:33:10Z","timestamp":1521934390000},"page":"3111-3116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and comfort of domestic bortezomib injection in real-life experience"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-5436","authenticated-orcid":false,"given":"Claudio","family":"Cerchione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Emanuele","family":"Pareto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Di Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Zacheo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Picardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,24]]},"reference":[{"key":"4155_CR1","doi-asserted-by":"publisher","unstructured":"Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK (2017) Annual report to the nation on the status of cancer, 1975\u20132014, featuring survival. J Natl Cancer Inst 109(9). https:\/\/doi.org\/10.1093\/jnci\/djx030","DOI":"10.1093\/jnci\/djx030"},{"issue":"1","key":"4155_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1600-0609.2012.01788.x","volume":"89","author":"M Delforge","year":"2012","unstructured":"Delforge M, Dhawan R, Robinson D Jr, Meunier J, Regnault A, Esseltine DL, Cakana A, Velde H, Richardson PG, San Miguel JF (2012) Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol 89(1):16\u201327","journal-title":"Eur J Haematol"},{"issue":"2","key":"4155_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1600-0609.2008.01179.x","volume":"82","author":"F Patriarca","year":"2009","unstructured":"Patriarca F, Petrucci MT, Bringhen S, Baldini L, Caravita T, Corradini P, Corso A, di Raimondo F, Falcone A, Ferrara F, Morabito F, Musto P, Offidani M, Petrini M, Rizzi R, Semenzato G, Tosi P, Vacca A, Cavo M, Boccadoro M, Palumbo A (2009) Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. Eur J Haematol 82(2):93\u2013105","journal-title":"Eur J Haematol"},{"issue":"5","key":"4155_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00277-009-0871-y","volume":"89","author":"HS Eom","year":"2010","unstructured":"Eom HS, Kim YK, Chung JS, Kim K, Kim HJ, Kim HY, Jin JY, Do YR, Oh SJ, Suh C, Seong CM, Kim CS, Lee DS, Lee JH (2010) Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean multiple myeloma working party (KMMWP). Ann Hematol 89(5):489\u2013497","journal-title":"Ann Hematol"},{"issue":"11","key":"4155_CR5","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","volume":"117","author":"F Gay","year":"2011","unstructured":"Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, Genuardi M, Romano A, Liberati AM, Siniscalchi A, Petrucci MT, Nozzoli C, Patriarca F, Offidani M, Ria R, Omede P, Bruno B, Passera R, Musto P, Boccadoro M, Sonneveld P, Palumbo A (2011) Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117(11):3025\u20133031","journal-title":"Blood"},{"issue":"1","key":"4155_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3816\/CLML.2010.n.008","volume":"10","author":"A Gozzetti","year":"2010","unstructured":"Gozzetti A, Fabbri A, Oliva S, Marchini E, Bocchia M, Defina M, Lauria F (2010) Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 10(1):68\u201372","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"4155_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/leu.2010.313","volume":"25","author":"P Kapoor","year":"2011","unstructured":"Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Mikhael JR, Roy V, Kyle RA, Greipp PR, Kumar S, Mandrekar SJ (2011) Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia 25(4):689\u2013696","journal-title":"Leukemia"},{"key":"4155_CR8","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2012-05-427815","volume":"120","author":"MV Mateos","year":"2012","unstructured":"Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, Lopez de la Guia A, Lopez J, Bengoechea E, Perez M, Polo M, Palomera L, de Arriba F, Gonzalez Y, Hernandez JM, Granell M, Bello JL, Bargay J, Penalver FJ, Ribera JM, Martin-Mateos ML, Garcia-Sanz R, Lahuerta JJ, Blade J, San-Miguel JF (2012) Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 120:2581\u20132588","journal-title":"Blood"},{"issue":"5","key":"4155_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","volume":"29","author":"S Zweegman","year":"2017","unstructured":"Zweegman S, Engelhardt M, Larocca A (2017) Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol 29(5):315\u2013321","journal-title":"Curr Opin Oncol"},{"key":"4155_CR10","first-page":"244","volume":"3","author":"VM M G","year":"2017","unstructured":"M G VM, M O PM, S B MTP et al (2017) Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: a comparison of two prospective trials. Am J Hematol 3:244\u2013250","journal-title":"Am J Hematol"},{"issue":"4","key":"4155_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2217\/imt.13.14","volume":"5","author":"A Romano","year":"2013","unstructured":"Romano A, Conticello C, Di Raimondo F (2013) Bortezomib for the treatment of previously untreated multiple myeloma. Immunotherapy 5(4):327\u2013352","journal-title":"Immunotherapy"},{"issue":"1","key":"4155_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","volume":"86","author":"MA Dimopoulos","year":"2011","unstructured":"Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, San Miguel JF (2011) Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 86(1):23\u201331","journal-title":"Eur J Haematol"},{"key":"4155_CR13","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","volume":"28","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Pia Falcone A, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol Off J Am Soc Clin Oncol 28:5101\u20135109","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"4155_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/leu.2012.160","volume":"27","author":"SZ Usmani","year":"2013","unstructured":"Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B, AlSayed Y, vanRhee F, Barlogie B (2013) Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: are patients now being cured? Leukemia 27(1):226\u2013232","journal-title":"Leukemia"},{"key":"4155_CR15","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3324\/haematol.13285","volume":"93","author":"P Moreau","year":"2008","unstructured":"Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, Harousseau JL (2008) Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 93:1908\u20131911","journal-title":"Haematologica"},{"key":"4155_CR16","doi-asserted-by":"crossref","unstructured":"Moreau P, Karamanesht II, Domnikova N, Kyselyova MY, Vilchevska K, Doronin VA, et al. (2011) Pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: effects of subcutaneous injection site and concentration, and patient characteristics. ASH Annual Meeting Abstracts 118(21):1863","DOI":"10.1182\/blood.V118.21.1863.1863"},{"issue":"5","key":"4155_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431\u2013440","journal-title":"Lancet Oncol"},{"issue":"19","key":"4155_CR18","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1182\/blood-2015-05-612960","volume":"126","author":"A Larocca","year":"2015","unstructured":"Larocca A, Palumbo A (2015) How I treat fragile myeloma patients. Blood 126(19):2179\u20132185","journal-title":"Blood"},{"issue":"2","key":"4155_CR19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4212\/cjhp.v67i2.1334","volume":"67","author":"SE Walker","year":"2014","unstructured":"Walker SE, Charbonneau LF, Law S (2014) Stability of bortezomib 2.5 mg\/mL in vials and syringes stored at 4 degrees C and room temperature (23 degrees C). Can J Hosp Pharm 67(2):102\u2013107","journal-title":"Can J Hosp Pharm"},{"key":"4155_CR20","doi-asserted-by":"publisher","first-page":"704928","DOI":"10.1155\/2009\/704928","volume":"2009","author":"A Bolognese","year":"2009","unstructured":"Bolognese A, Esposito A, Manfra M, Catalano L, Petruzziello F, Martorelli MC et al (2009) An NMR study of bortezomib degradation under clinical use conditions. Adv Hematol 2009:704928","journal-title":"Adv Hematol"},{"issue":"4","key":"4155_CR21","first-page":"1579","volume":"34","author":"D Leveque","year":"2014","unstructured":"Leveque D (2014) Subcutaneous administration of anticancer agents. Anticancer Res 34(4):1579\u20131586","journal-title":"Anticancer Res"},{"issue":"2","key":"4155_CR22","first-page":"273","volume":"21","author":"D Lev\u00eaque","year":"2007","unstructured":"Lev\u00eaque D, Carvalho MC, Review MF (2007) Clinical pharmacokinetics of bortezomib. In Vivo 21(2):273\u2013278","journal-title":"In Vivo"},{"issue":"5","key":"4155_CR23","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S1470-2045(11)70098-5","volume":"12","author":"MV Mateos","year":"2011","unstructured":"Mateos MV (2011) Subcutaneous bortezomib: a step towards optimised drug use. Lancet Oncol 12(5):410\u2013411","journal-title":"Lancet Oncol"},{"issue":"5","key":"4155_CR24","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/ejh.12705","volume":"96","author":"C Cerchione","year":"2016","unstructured":"Cerchione C, Lucignano M, Pane F, Catalano L (2016) Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed\/refractory multiple myeloma: comments to the article by Romano et al. Eur J Haematol 96(5):544. https:\/\/doi.org\/10.1111\/ejh.12705","journal-title":"Eur J Haematol"},{"issue":"3","key":"4155_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/ejh.12325","volume":"93","author":"A Romano","year":"2014","unstructured":"Romano A, Chiarenza A, Conticello C, Cavalli M, Vetro C, Di Raimondo C et al (2014) Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed\/refractory myeloma patients. Eur J Haematol 93(3):207\u2013213","journal-title":"Eur J Haematol"},{"issue":"9","key":"4155_CR26","doi-asserted-by":"publisher","first-page":"908","DOI":"10.6004\/jnccn.2009.0061","volume":"7","author":"KC Anderson","year":"2009","unstructured":"Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F, National Comprehensive Cancer Network (2009) NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Cancer Netw 7(9):908\u2013942","journal-title":"J Natl Compr Cancer Netw"},{"issue":"2","key":"4155_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00520-014-2490-y","volume":"23","author":"C Cerchione","year":"2015","unstructured":"Cerchione C, Catalano L, Pareto AE, Picardi M, Pane F (2015) Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. Support Care Cancer 23(2):301\u2013302","journal-title":"Support Care Cancer"},{"issue":"12","key":"4155_CR28","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1007\/s00520-016-3430-9","volume":"24","author":"C Cerchione","year":"2016","unstructured":"Cerchione C, Catalano L, Peluso I, Nappi D, Di Perna M, Salvatore D et al (2016) Managing neutropenia by pegfilgrastim in patients affected by relapsed\/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone. Support Care Cancer 24(12):4835\u20134837","journal-title":"Support Care Cancer"},{"issue":"8","key":"4155_CR29","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346","journal-title":"Lancet Oncol"},{"key":"4155_CR30","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"MV Mateos","year":"2010","unstructured":"Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, de Paz R et al (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11:934\u2013941","journal-title":"Lancet Oncol"},{"key":"4155_CR31","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3324\/haematol.12106","volume":"93","author":"MV Mateos","year":"2008","unstructured":"Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, Garcia-Larana J, Garcia-Sanz R, Blade J, Prosper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF (2008) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 93:560\u2013565","journal-title":"Haematologica"},{"issue":"9","key":"4155_CR32","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2217\/imt.11.104","volume":"3","author":"I Spicka","year":"2011","unstructured":"Spicka I, Mateos MV, Redman K, Dimopoulos MA, Richardson PG (2011) An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation. Immunotherapy 3(9):1033\u20131040","journal-title":"Immunotherapy"},{"issue":"21","key":"4155_CR33","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.V116.21.3029.3029","volume":"116","author":"S Bringhen","year":"2010","unstructured":"Bringhen S, Larocca A, Rossi D, Romano A, Genuardi M, Ria R et al (2010) Efficacy and safety of once weekly bortezomib in multiple myeloma patients. Blood 116(21):1248\u20131249","journal-title":"Blood"},{"issue":"18","key":"4155_CR34","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","volume":"117","author":"M Dimopoulos","year":"2011","unstructured":"Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksac M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S, on behalf of the International Myeloma Workshop Consensus Panel 3 (2011) Consensus recommendations for standard investigative workup: report of the international myeloma workshop consensus panel 3. Blood 117(18):4701\u20134705","journal-title":"Blood"},{"issue":"12","key":"4155_CR35","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","volume":"97","author":"B Arnulf","year":"2012","unstructured":"Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, Moreau P (2012) Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 97(12):1925\u20131928","journal-title":"Haematologica"},{"issue":"12","key":"4155_CR36","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1007\/s00520-016-3363-3","volume":"24","author":"M Touati","year":"2016","unstructured":"Touati M, Lamarsalle L, Moreau S, Vergnenegre F, Lefort S, Brillat C et al (2016) Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in outpatient hospital and hospital care at home. Support Care Cancer 24(12):5007\u20135014","journal-title":"Support Care Cancer"},{"issue":"4","key":"4155_CR37","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ajh.23641","volume":"89","author":"F Morabito","year":"2014","unstructured":"Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, Mazzone C, Gottardi D, Omed\u00e8 P, Zweegman S, Jos\u00e9 Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Isabel Turel A, Marina Liberati A, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A, San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M (2014) Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: a retrospective case-matched study. Am J Hematol 89(4):355\u2013362","journal-title":"Am J Hematol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4155-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4155-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4155-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:44:57Z","timestamp":1751499897000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4155-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,24]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["4155"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4155-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,24]]},"assertion":[{"value":"24 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}